Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554745 | 0.86 | MAP2K1 (0.53) | MAP2K1CA2CA1 | |
| SCHEMBL1680940 | 0.80 | MAP2K1 (0.45) | ALDH1A1MAP2K1MEN1MAPTKMT2A | |
| SCHEMBL1495222 | 0.76 | MAP2K1 (0.46) | MAP2K1CA2 | |
| SCHEMBL1555015 | 0.72 | MAP2K1 (0.50) | MAP2K1CA2CA1 | |
| SCHEMBL13556478 | 0.71 | MAP2K1 (0.55) | MAP2K1CA2CA1 | |
| SCHEMBL1111202 | 0.70 | MAP2K1 (0.81) | MAP2K1CA2CA1 | |
| SCHEMBL12002495 | 0.70 | MAP2K1 (0.60) | MAP2K1CA2CA1 | |
| SCHEMBL12002496 | 0.70 | MAP2K1 (0.60) | MAP2K1CA2CA1 | |
| SCHEMBL1555556 | 0.70 | MAP2K1 (0.52) | MAP2K1CA2CA1 | |
| SCHEMBL1111366 | 0.69 | MAP2K1 (0.53) | MAP2K1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962606-B2 | Substituted benzosulphonamides | BAYER INTELLECTUAL PROPERTY GMBH (US) | 2015-02-24 | — | — | US | disclosed |
| US-20120269803-A1 | SUBSTITUTED BENZOSULPHONAMIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120269804-A1 | SUBSTITUTED BENZOSULPHONAMIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| EP-2491016-A1 | SUBSTITUTED BENZOSULPHONAMIDES | Bayer Pharma Aktiengesellschaft (DE) | 2012-08-29 | — | — | EP | disclosed |
| EP-2491015-A1 | SUBSTITUTED BENZOSULPHONAMIDES | Bayer Pharma Aktiengesellschaft (DE) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011047788-A1 | SUBSTITUTED BENZOSULPHONAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011047795-A1 | SUBSTITUTED BENZOSULPHONAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269803-A1 | SUBSTITUTED BENZOSULPHONAMIDES | VEGFA, CCND2, F12 | ALDH1A1 1312/4885MAP2K1 3488/4885CA2 3787/4885 |
| US-20120269804-A1 | SUBSTITUTED BENZOSULPHONAMIDES | VEGFA, CCND2, F12 | ALDH1A1 1312/4885MAP2K1 3488/4885CA2 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.